Cancer drug interaction study: what happens when you add an antibiotic?
NCT ID NCT00750841
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This Phase I study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib. 64 adults with advanced solid tumors who have not responded to standard treatments will take cediranib alone and then with rifampicin. The goal is to measure drug levels in the blood and check for side effects, helping guide future use of cediranib with other medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Dundee, DD1 9SY, United Kingdom
-
Research Site
Glasgow, G12 0YN, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
London, SE1 9RT, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cediranib (experimental cancer drug) and rifampicin (antibiotic)
What this could lead to
If successful, this study could help doctors understand how to safely combine cediranib with other drugs that affect the same liver enzymes.
What could go wrong
This is a very early, small study focused on drug interactions, not on treating cancer. It may not lead to any direct benefit for participants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.